EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis

Nizar Chahin, Gregory Sahagian, Marc H Feinberg, C Andrew Stewart, Christopher M Jewell, Metin Kurtoglu, Miloš D Miljković iD, Tuan Vu, Tahseen Mozaffar, James F Howard iD, MG‐001 Study Group

Annals of Clinical and Translational Neurology · 2025-11 · 12 (11) · 2358-2366

DOI: 10.1002/acn3.70167 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 26.08.2025. Verfasst von Nizar Chahin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Oregon Health and Sciences University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: B-Cell Maturation Antigen, Immunotherapy, Adoptive, Myasthenia Gravis, RNA, Messenger. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, Cartesian Therapeutics, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG). These findings provide insight into the potential applicability of BCMA‐targeted rCAR‐T therapy for antibody‐mediated autoimmune diseases.

Methods

In the Phase 2a part of the study, Descartes‐08 was administered at 52.5 × 10 6 CAR+ cells/kg per infusion with varying dosing frequencies as an outpatient treatment and without lymphodepletion chemotherapy. A subset of participants received Descartes‐08 as six weekly infusions and were followed long term with assessments conducted at 2, 3, 6, 9, and 12 months.

Results

All seven participants who received six weekly infusions of Descartes‐08 exhibited clinically meaningful improvement in common MG severity scales (MG Composite, MG Activities of Daily Living, Quantitative MG scores, and Quality of Life 15‐revised) at Month 3 without significant toxicity. At Month 9 follow‐up, all participants continued to experience marked clinically meaningful improvements. Five out of seven participants maintained the response at Month 12. A third participant experienced a relapse approximately 6 months after completing on‐study follow‐up. All three participants who experienced loss of clinical effects were retreated. Two had rapid improvement in clinical scores with minimal symptom expression at Week 8, which was maintained through 12 months of retreatment follow‐up. The third participant experienced similar improvement in MG severity scores to their initial treatment.

Interpretation

These data support continued development of Descartes‐08 in myasthenia gravis and other autoantibody‐associated autoimmune disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B-Cell Maturation AntigenImmunotherapy, AdoptiveMyasthenia GravisRNA, MessengerAdultAgedFemaleHumansMaleMiddle AgedFollow-Up StudiesTreatment OutcomeCross-Over Studies

Stichwörter der Autor:innen

BCMACAR‐TDescartes‐08autoimmunemyasthenia gravis

Substanzen

B-Cell Maturation AntigenRNA, Messenger

Autor:innen und Institutionen

  • Department of Neurology, Oregon Health and Sciences University, Portland, Oregon, USA.
  • Neurology Center of Southern California, San Diego, California, USA.
  • SFM Research, Boca Raton, Florida, USA.
  • Cartesian Therapeutics, Frederick, Maryland, USA.
  • Department of Neurology, University of South Florida, Tampa, Florida, USA.
  • Department of Neurology, University of California Irvine, California, USA.

ORCID-Profile: Miloš D Miljković, James F Howard

Förderung

  • NINDS NIH HHS
  • Cartesian Therapeutics
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Chahin, N., Sahagian, G., Feinberg, M. H., Stewart, C. A., Jewell, C. M., Kurtoglu, M., Miljković, M. D., Vu, T., Mozaffar, T., Howard, J. F., & MG‐001 Study Group (2025). Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis. Annals of Clinical and Translational Neurology, 12(11), 2358-2366. https://doi.org/10.1002/acn3.70167

Vancouver

Chahin N, Sahagian G, Feinberg MH, Stewart CA, Jewell CM, Kurtoglu M, et al. Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis. Annals of Clinical and Translational Neurology. 2025;12(11):2358-2366. doi:10.1002/acn3.70167

BibTeX
@article{Chahin2025,
  author = {Chahin, Nizar and Sahagian, Gregory and Feinberg, Marc H and Stewart, C Andrew and Jewell, Christopher M and Kurtoglu, Metin and Miljković, Miloš D and Vu, Tuan and Mozaffar, Tahseen and Howard, James F and MG‐001 Study Group, MG‐001 Study Group},
  title = {Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  volume = {12},
  number = {11},
  pages = {2358--2366},
  doi = {10.1002/acn3.70167}
}
Kostenlos starten →